Congresses and Events

Three-year Results from the EVOLVE II Randomized Trial presented at ACC

EVOLVE II clinical trial, outstanding Safety and Performance EVOLVE II clinical trial, outstanding Safety and Performance

Three-year follow-up from EVOLVE II trial presented by Dr. Dean Kereiakes supports longer-term safety and efficacy of the novel abluminal bioabsorbable polymer SYNERGY™ everolimus-eluting stent in a broad range of patients undergoing PCI.

Learn more

Synergy™ BP Stent Launches 48mm Length

Heal long lesions with confidence Heal long lesions with confidence

Long lesions represent a complex lesion subset that is associated with increased safety related events, reduced efficacy and increased procedure time. SYNERGY™ BP Stent was designed for quality healing and safety over time and with the addition of a 48mm length it has a complete size matrix to address these complex lesions.

Learn more

Boston Scientific announces Agreement to acquire Symetis

ACURATE TA™ ACURATE TA™

Boston Scientific announced a definitive agreement to acquire Symetis SA. The Symetis portfolio includes the ACURATE TA™ and ACURATE neo/TF valve* systems for use in the treatment of high-risk patients suffering from severe and symptomatic aortic valve stenosis.

Learn more

Top